Marisa Wexler, MS,  senior science writer—

Even though most people with cystic fibrosis (CF) place considerable importance on being prepared in making decisions about a lung transplant, many lack knowledge of the procedure and speak of feeling unprepared, especially those of lower socioeconomic status, a survey of adults at a University of Washington CF clinic…

Genexys Biomed has been awarded a $320,000 grant to advance the development of a novel gene therapy for cystic fibrosis (CF). The small business innovation research grant was given by the National Heart, Lung, and Blood Institute, a branch of the National Institutes of Health. The “grant is a…

The first cystic fibrosis (CF) patient has been dosed in Part A of a Phase 2 clinical trial in Europe that’s testing Enterprise Therapeutics‘ novel CF treatment candidate ETD001. The Phase 2a trial (NCT06478706) is still recruiting adults with CF at a few sites in the U.K. and…

Authorities in the U.S. and Europe are reviewing applications from Vertex Pharmaceuticals seeking approval of the company’s novel CFTR modulator triple combination, vanzacaftor, tezacaftor and deutivacaftor.  Vertex is asking that the vanza combo be approved for people with cystic fibrosis (CF) ages 6 and older who carry…

During pulmonary exacerbation in cystic fibrosis (CF), bacterial communities in the lungs tend to change in one of two general patterns, and better understanding these patterns may help predict how patients will respond to antibiotic treatments. That’s according to the study, “Microbial community organization designates distinct…

Two Massachusetts-based companies, Nanite and Saliogen Therapeutics, are teaming up on a new research project that aims to create a genetic medicine with the potential to treat cystic fibrosis (CF). “Nanite’s relationship with SalioGen is consequential in discovering safe polymeric nanoparticles for a transformative treatment for CF,”…

This year’s “Fishing for a Cure,” an annual fundraiser hosted by Constellation Energy Corporation, has raised $70,000 for the Cystic Fibrosis Foundation, a nonprofit that helps to support people living with cystic fibrosis (CF) and to fund research for new treatments. “We are in shock by the incredible…

Evoq Bio said it successfully completed a meeting with the U.S. Food and Drug Administration (FDA), held to discuss the development of its inhaled nanoparticle therapy for treating bacterial lung infections in people with cystic fibrosis (CF) and other lung disorders. According to the company, a subsidiary of…

Phage therapy, a promising strategy for treating antibiotic-resistant lung infections that’s currently in clinical trials, can trigger the release of inflammatory signaling molecules from human lung cells, with different types of phages triggering a different set of signaling molecules. That’s according to a study, “Lytic bacteriophages induce…

Treatment with Kaftrio (elexacaftor/tezacaftor/ivacaftor) helps increase fat stores in adults with cystic fibrosis (CF), especially those who are underweight, a study found. Researchers also found small, though statistically significant, increases in muscle mass in patients who started on Kaftrio. The results showed that Kaftrio mainly affects fat tissues,…